Ocular Side Effects of Aromatase Inhibitor Endocrine Therapy in Breast Cancer - A Review
- PMID: 34972698
- PMCID: PMC8765131
- DOI: 10.21873/invivo.12674
Ocular Side Effects of Aromatase Inhibitor Endocrine Therapy in Breast Cancer - A Review
Abstract
Background: Aromatase inhibitor therapy is currently the preferred choice in postmenopausal women with estrogen receptor positive breast cancer. This article reviews the ocular side effects of treatment with aromatase inhibitors (AIs) in patients with breast cancer.
Materials and methods: A comprehensive search was performed on PubMed, Web of Science and Google scholar.
Results: After duplication removal, 14 clinical studies and 5 case reports, published between 2008 and 2021, were identified. Most frequently, AI treatment resulted in minor to moderate dry eye symptoms. "De novo" onset of Sjogren syndrome during AI therapy was also reported. Retinal and optic nerve side effects varied from mild, subclinical anatomic and functional impairment to severe decreased vision, secondary to hemi-central retinal artery occlusion, bilateral optic neuritis or uveitis with bilateral macular edema.
Conclusion: Visual disturbances encountered during AI treatment may be underestimated. Ophthalmic screening is important for early detection and appropriate treatment.
Keywords: Breast cancer; anastrozole; aromatase inhibitors; dry eye; endocrine therapy; ocular side-effects; review.
Copyright © 2022 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Conflict of interest statement
The Authors declare no conflicts of interest in relation to this study.
Similar articles
-
Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women.Curr Med Res Opin. 2006 Aug;22(8):1609-21. doi: 10.1185/030079906X115667. Curr Med Res Opin. 2006. PMID: 16870085 Review.
-
Breast cancer medications and vision: effects of treatments for early-stage disease.Curr Eye Res. 2011 Oct;36(10):867-85. doi: 10.3109/02713683.2011.594202. Epub 2011 Aug 5. Curr Eye Res. 2011. PMID: 21819259 Free PMC article. Review.
-
Aromatase inhibitor-associated arthralgia syndrome.Breast. 2007 Jun;16(3):223-34. doi: 10.1016/j.breast.2007.01.011. Epub 2007 Mar 21. Breast. 2007. PMID: 17368903 Review.
-
Management of bone loss in postmenopausal breast cancer patients treated with aromatase inhibitors.Acta Reumatol Port. 2015 Oct-Dec;40(4):323-30. Acta Reumatol Port. 2015. PMID: 26922195 Review.
-
Risk of ocular adverse events with aromatase inhibitors.Can J Ophthalmol. 2024 Oct;59(5):e431-e434. doi: 10.1016/j.jcjo.2023.10.013. Epub 2023 Nov 3. Can J Ophthalmol. 2024. PMID: 37931898
Cited by
-
Palinopsia associated with the CDK4/6 inhibitor ribociclib during the first-line treatment of metastatic breast cancer: two case reports.Front Oncol. 2024 Dec 19;14:1430341. doi: 10.3389/fonc.2024.1430341. eCollection 2024. Front Oncol. 2024. PMID: 39749028 Free PMC article.
-
Ocular side effects of anticancer agents used in the treatment of gynecologic cancers.Gynecol Oncol. 2024 Sep;188:147-157. doi: 10.1016/j.ygyno.2024.06.003. Epub 2024 Jul 4. Gynecol Oncol. 2024. PMID: 38964252 Free PMC article. Review.
-
Influence of tamoxifen on ocular morphology and function.Oncologist. 2025 May 8;30(5):oyaf103. doi: 10.1093/oncolo/oyaf103. Oncologist. 2025. PMID: 40377437 Free PMC article.
-
Corneal changes in estrogen-dependent breast cancer after hormonal treatment.Sci Rep. 2025 Aug 19;15(1):30330. doi: 10.1038/s41598-025-16065-7. Sci Rep. 2025. PMID: 40830401 Free PMC article.
-
Qualitative exploration of women's experiences of vasomotor symptoms to support the content validity of patient-reported outcomes.J Patient Rep Outcomes. 2025 Jul 1;9(1):79. doi: 10.1186/s41687-025-00914-0. J Patient Rep Outcomes. 2025. PMID: 40591096 Free PMC article.
References
-
- Breast cancer. World Health Organization. Available at: https://www.who.int/news-room/fact-sheets/detail/breast-cancer. [Last accessed on September 10, 2021]
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical